152 related articles for article (PubMed ID: 27765799)
61. Mechanisms of ErbB receptor negative regulation and relevance in cancer.
Fry WH; Kotelawala L; Sweeney C; Carraway KL
Exp Cell Res; 2009 Feb; 315(4):697-706. PubMed ID: 18706412
[TBL] [Abstract][Full Text] [Related]
62. The p140Cap adaptor protein as a molecular hub to block cancer aggressiveness.
Salemme V; Angelini C; Chapelle J; Centonze G; Natalini D; Morellato A; Taverna D; Turco E; Ala U; Defilippi P
Cell Mol Life Sci; 2021 Feb; 78(4):1355-1367. PubMed ID: 33079227
[TBL] [Abstract][Full Text] [Related]
63. Male breast cancer: a disease distinct from female breast cancer.
Gucalp A; Traina TA; Eisner JR; Parker JS; Selitsky SR; Park BH; Elias AD; Baskin-Bey ES; Cardoso F
Breast Cancer Res Treat; 2019 Jan; 173(1):37-48. PubMed ID: 30267249
[TBL] [Abstract][Full Text] [Related]
64. The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery.
Alaoui-Jamali MA; Qiang H
Drug Resist Updat; 2003 Apr; 6(2):95-107. PubMed ID: 12729807
[TBL] [Abstract][Full Text] [Related]
65. Update on HER-2 as a target for cancer therapy: alternative strategies for targeting the epidermal growth factor system in cancer.
Gullick WJ
Breast Cancer Res; 2001; 3(6):390-4. PubMed ID: 11737891
[TBL] [Abstract][Full Text] [Related]
66. Erbb4 Signaling: an overlooked backup system?
Ni Y; Zhang S
Cell Cycle; 2015; 14(11):1623. PubMed ID: 25945734
[No Abstract] [Full Text] [Related]
67. ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion.
Feigin ME; Muthuswamy SK
Exp Cell Res; 2009 Feb; 315(4):707-16. PubMed ID: 19022245
[TBL] [Abstract][Full Text] [Related]
68. Targeting ERBB receptors to inhibit metastasis: old hopes and new certainties.
Angelucci A
Curr Cancer Drug Targets; 2009 Feb; 9(1):1-18. PubMed ID: 19200048
[TBL] [Abstract][Full Text] [Related]
69. Are we close to the end of the primary tumor resection discussion for de novo stage IV BC?
Soran A
Eur J Surg Oncol; 2019 Feb; 45(2):81-82. PubMed ID: 30528045
[No Abstract] [Full Text] [Related]
70. Editorial for the Special Issue "New Drugs for Breast Cancer Treatment".
Acconcia F
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142174
[TBL] [Abstract][Full Text] [Related]
71. Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation.
Nagashima T; Shimodaira H; Ide K; Nakakuki T; Tani Y; Takahashi K; Yumoto N; Hatakeyama M
J Biol Chem; 2014 Jul; 289(30):20491. PubMed ID: 25063842
[No Abstract] [Full Text] [Related]
72. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
Jackisch C; Lammers P; Jacobs I
Breast; 2017 Apr; 32():199-216. PubMed ID: 28236776
[TBL] [Abstract][Full Text] [Related]
73. Risk Factors and Preventions of Breast Cancer.
Sun YS; Zhao Z; Yang ZN; Xu F; Lu HJ; Zhu ZY; Shi W; Jiang J; Yao PP; Zhu HP
Int J Biol Sci; 2017; 13(11):1387-1397. PubMed ID: 29209143
[TBL] [Abstract][Full Text] [Related]
74. Family history and risk of breast cancer: an analysis accounting for family structure.
Brewer HR; Jones ME; Schoemaker MJ; Ashworth A; Swerdlow AJ
Breast Cancer Res Treat; 2017 Aug; 165(1):193-200. PubMed ID: 28578505
[TBL] [Abstract][Full Text] [Related]
75. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.
Jung M; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DD; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ
Cancer Res; 2017 Feb; 77(4):971-981. PubMed ID: 27923830
[TBL] [Abstract][Full Text] [Related]
76. Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer.
Kim A; Jang MH; Lee SJ; Bae YK
J Breast Cancer; 2017 Jun; 20(2):150-159. PubMed ID: 28690651
[TBL] [Abstract][Full Text] [Related]
77. Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?
Cordo Russo RI; Chervo MF; Madera S; Charreau EH; Elizalde PV
Horm Cancer; 2019 Jun; 10(2-3):64-70. PubMed ID: 30656558
[TBL] [Abstract][Full Text] [Related]
78. Cancer Statistics, 2017.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2017 Jan; 67(1):7-30. PubMed ID: 28055103
[TBL] [Abstract][Full Text] [Related]
79. A Cell-Penetrating Peptide Improves Anti-HER2 Single-Chain Variable Fragment Internalization and Antitumor Activity against HER2-Positive Breast Cancer In Vitro and In Vivo.
Li J; Zhou Y; Su Z; Li X; Zhang L; Li S
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542884
[TBL] [Abstract][Full Text] [Related]
80. Advances in PET/CT Imaging for Breast Cancer.
de Jong D; Desperito E; Al Feghali KA; Dercle L; Seban RD; Das JP; Ma H; Sajan A; Braumuller B; Prendergast C; Liou C; Deng A; Roa T; Yeh R; Girard A; Salvatore MM; Capaccione KM
J Clin Med; 2023 Jul; 12(13):. PubMed ID: 37445572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
